Neuphoria Therapeutics

Update in progress

NEUP (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on novel allosteric ion channel modulators for CNS disorders. Its lead candidate, BNC210, is a selective negative allosteric modulator of the alpha-7 receptor for social anxiety disorder and is in phase 2b for PTSD. The portfolio includes BNC101 (anti-cancer stem cell–targeting monoclonal antibody) and BNC105 for cancer, plus preclinical programs NextGen and a Kv3.1/3.2 agonist. Formerly Bionomics, renamed in Dec 2024; founded 1996, based in Burlington, MA, with Merck collaboration on A7 PAMs.

Company score

Sentiment: -0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.10; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.40; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.30; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive